Influence of Remifentanil on the Pharmacokinetics and Pharmacodynamics of Remimazolam in Healthy Volunteers
Authors' conclusion
A pharmacokinetic and pharmacodynamic drug-drug interaction between remimazolam and remifentanil was quantified in this clinical trial.
Study context
- Population
- Healthy volunteers
- Participants
- 24 volunteers
- Comparison
- Remimazolam TCI alone vs with remifentanil 0.5 ng/ml vs with remifentanil 0.1 to 4.0 ng/ml
- Remimazolam alonen = 24reference
- Remifentanil 0.5 ng/mln = 24
- Remifentanil 0.1 to 4.0 ng/mln = 24
- Outcome
- Influence of remifentanil on remimazolam sedation (MOAAS, BIS, tolerance to laryngoscopy or tetanic stimulation) and target concentrations maximising MOAAS 2 or 3
Methodological detailsthree-period
- Three-period
Main finding
As reported in the abstract
Remifentanil reduced apparent clearance of CNS7054; half-maximum inhibition
8.0
ng/ml; 95% CI 5.5 to 13.4
Simulated highest probability of Modified Observer's Assessment of Alertness and Sedation (MOAAS) 2 or 3: remimazolam 275 ng/ml with 0 ng/ml remifentanil
45%
Simulated highest probability of MOAAS 2 or 3: remimazolam 250 ng/ml with 0.1 ng/ml remifentanil
45%
Simulated highest probability of MOAAS 2 or 3: remimazolam 200 ng/ml with 0.5 ng/ml remifentanil
44%
Further findings
Simulated highest probability of TOTS and TOL
- TOTS, at highest studied target concentrations
- 93.3%
- TOL, at highest studied target concentrations
- 85.5%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →